Nov 15 (Reuters) - The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, the regulator said. (Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.28 USD | -0.56% | 0.00% | +40.43% |
Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.43% | 290M | |
+4.06% | 69.85B | |
+11.77% | 8.98B | |
-14.44% | 4.89B | |
+41.60% | 4.44B | |
+5.96% | 3.95B | |
+22.62% | 2.49B | |
-19.32% | 2.4B | |
-27.04% | 2.28B | |
+7.97% | 1.96B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- U.S. FDA approves CorMedix's antimicrobial drug